suggests that the investigational dual #GLP-1/GIP receptor agonist olatorepatide may deliver weight-loss efficacy comparable to Eli Lilly and Companys Zepbound (tirzepatide) Employer
(b) a paucity of computer literacy in the patient population, meaning several potential participants were unable to use MS Teams for the interviews
Recalls & Warnings January 21, 2018 Joint Supplement Recalled for Salmonella Risk On January 21, 2018, Arthri-D, LLC announced a recall of its joint pain supplement, Arthri-D (120 count), due to possible Salmonella contamination
What's Inside Ascorbic Acid Injection Ascorbic acid (vitamin C) may be prescribed to reduce the risk of or support vitamin C deficiency
Prescribing, Safety, and the Future of GLP-1s Are you considering treatment that involves GLP-1 receptor agonists
After several weeks of training for all study-related procedures, 70 out of 85 monkeys were selected based on blood chemistry and BW data collected at the end of the training period